Alnylam

Alnylam posts strong Onpattro sales as competition heats up
Biopharma Dive
Thu, 05/2/19 - 08:12 pm
Alnylam
Onpattro
earnings
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More
Xconomy
Sun, 04/21/19 - 12:16 am
FDA
CRISPR
gene therapy
Achaogen
Allergan
Alnylam
Adverum Biotechnologies
Blackstone Life Sciences
Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III
BioCentury
Fri, 04/12/19 - 11:33 pm
Alnylam
FDA
givosiran
acute hepatic porphyria
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Endpoints
Thu, 04/11/19 - 10:11 am
Regeneron
Alnylam
R&D
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Mon, 04/8/19 - 09:56 am
Alnylam
Regeneron
RNAi
eye health
brain diseases
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise
Endpoints
Fri, 03/22/19 - 10:11 pm
Alnylam
RNAi
Pharma CEOs
John Maraganore
exective pay
Data in Hand, Alnylam To Seek OK For Second RNAi Drug
Xconomy
Wed, 03/6/19 - 10:07 am
Alnylam
RNAi
FDA
acute hepatic porphyria
givosiran
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
Sat, 03/2/19 - 12:44 pm
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Alnylam Pharmaceuticals Is Launched and Ready for More
Motley Fool
Tue, 02/12/19 - 11:32 am
Alnylam
ATTR amyloidosis
Onpattro
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Alnylam CEO talks politics, gene therapy and not becoming Pfizer
BioPharma Dive
Sun, 12/16/18 - 12:12 am
Alnylam
RNAi
Onpattro
Pharma CEOs
John Maraganore
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst
Fierce Pharma
Mon, 11/19/18 - 11:31 am
Alnylam
RNAi
Onpattro
hATTR amyloidosis
Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug
Marketwatch
Mon, 10/15/18 - 12:05 pm
Alnylam
FDA
givosiran
acute hepatic porphyria
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
Fri, 10/5/18 - 09:38 pm
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial
Pharmaceutical Business Review
Thu, 10/4/18 - 06:55 pm
Alnylam
RNAi
ALN-AAT02
MHRA
UK
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
CP Wire
Fri, 09/28/18 - 10:34 am
Alnylam
Patisiran
Onpattro
Japan
hATTR amyloidosis
Alnylam, with positive data on second gene-silencing drug, plans filing to FDA
Stat
Thu, 09/27/18 - 10:12 am
Alnylam
gene-silencing
givosiran
FDA
acute hepatic porphyrias
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
CP Wire
Fri, 09/14/18 - 09:40 am
Alnylam
Patisiran
hATTR amyloidosis
Onpattro

Pages